![Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2](https://oncodaily.com/pub/uploads/2024/04/4cd32b79736f4c19b4d7f68fbd04c4f0.jpg)
Photo from Chul Kim/X
Apr 26, 2024, 09:26
Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter:
”First-line treatment for EGFR mutant NSCLC is getting complex with recent approval of FLAURA2.
Would higher risk populations benefit more (e.g. L858R, co-mutations including TP53, RB1, CNS met)?
Thoughtful discussion and great talk by Rachel Sanborn.”
Source: Chul Kim/X
Jul 1, 2024, 19:16